Combination Therapy of PPARγ Ligands and Inhibitors of Arachidonic Acid in Lung Cancer
2008
Combination Therapy of PPARγ Ligands and Arachidonic Acid Inhibitors in Lung Cancer
publication
Evidence: moderate
Author Information
Author(s): Jordi Tauler, James L. Mulshine
Primary Institution: Rush University Medical Center
Hypothesis
Targeting LOX/COX enzymes and activating PPARγ will reduce lung cancer cell growth.
Conclusion
Combining LOX and COX inhibitors with PPARγ ligands may enhance therapeutic effects in lung cancer treatment.
Supporting Evidence
- Lung cancer is the leading cause of cancer death in the U.S.
- Chronic inflammation may contribute to lung cancer progression.
- PPARγ activation can reduce cell growth in lung cancer.
- Combination therapies have shown promise in reducing cancer cell growth.
Takeaway
This study suggests that using a mix of certain drugs can help fight lung cancer better than using just one type of drug.
Methodology
The study reviews existing literature on the effects of PPARγ activation and LOX/COX inhibition on lung cancer.
Limitations
The review does not provide new experimental data and relies on existing studies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website